PROSPECTIVE ANALYSIS OF COMPLETE OBSERVED RESPONSES IN SUNITINIB IN PATIENTS WITH METASTATIC KIDNEY CANCER (mRCC)
Phase of Trial: Phase IV
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms APERCU
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 17 Jun 2016 Status changed from active, no longer recruiting to recruiting.
- 02 May 2016 Status changed from recruiting to active, no longer recruiting.